全文获取类型
收费全文 | 88806篇 |
免费 | 5099篇 |
国内免费 | 303篇 |
专业分类
耳鼻咽喉 | 1057篇 |
儿科学 | 2410篇 |
妇产科学 | 2115篇 |
基础医学 | 11776篇 |
口腔科学 | 2184篇 |
临床医学 | 7496篇 |
内科学 | 21489篇 |
皮肤病学 | 1773篇 |
神经病学 | 7852篇 |
特种医学 | 3119篇 |
外国民族医学 | 6篇 |
外科学 | 11108篇 |
综合类 | 507篇 |
一般理论 | 38篇 |
预防医学 | 8631篇 |
眼科学 | 1371篇 |
药学 | 6018篇 |
中国医学 | 236篇 |
肿瘤学 | 5022篇 |
出版年
2023年 | 724篇 |
2022年 | 983篇 |
2021年 | 2215篇 |
2020年 | 1405篇 |
2019年 | 2003篇 |
2018年 | 4242篇 |
2017年 | 2927篇 |
2016年 | 2253篇 |
2015年 | 2086篇 |
2014年 | 2749篇 |
2013年 | 4218篇 |
2012年 | 5925篇 |
2011年 | 6221篇 |
2010年 | 3316篇 |
2009年 | 2668篇 |
2008年 | 5189篇 |
2007年 | 5243篇 |
2006年 | 4917篇 |
2005年 | 4803篇 |
2004年 | 4401篇 |
2003年 | 4176篇 |
2002年 | 4000篇 |
2001年 | 2234篇 |
2000年 | 2459篇 |
1999年 | 1741篇 |
1998年 | 713篇 |
1997年 | 524篇 |
1996年 | 481篇 |
1995年 | 437篇 |
1994年 | 369篇 |
1993年 | 371篇 |
1992年 | 703篇 |
1991年 | 601篇 |
1990年 | 577篇 |
1989年 | 524篇 |
1988年 | 496篇 |
1987年 | 504篇 |
1986年 | 434篇 |
1985年 | 443篇 |
1984年 | 368篇 |
1983年 | 295篇 |
1982年 | 212篇 |
1981年 | 182篇 |
1980年 | 173篇 |
1979年 | 238篇 |
1978年 | 201篇 |
1977年 | 181篇 |
1976年 | 164篇 |
1975年 | 165篇 |
1973年 | 159篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
José Ignacio Bilbao Mercedes Arias Jesús María Longo Pedro Luis Alejandre María Teresa Betés Arlette María Elizalde 《Cardiovascular and interventional radiology》1997,20(2):149-153
Percutaneous embolization of large portosystemic collaterals was performed in three patients following placement of a transjugular
intrahepatic portosystemic shunt in order to improve hepatopetal portal flow. Improved hepatic portal perfusion was achieved
in these cases, thereby theoretically reducing the risk of chronic hepatic encephalopathy. 相似文献
92.
M. Bergström G. Westerberg G. Németh M. Traut G. Gross G. Greger H. Müller-Peltzer A. Safer S.-Å. Eckernäs A. Grahnér B. Långström 《European journal of clinical pharmacology》1997,52(2):121-128
Objective: The aim of the study was to investigate whether or not esuprone binds substantially to MAO-A in the human brain. Methods: In a randomised double-blind placebo-controlled study 16 male healthy volunteers were examined␣with positron emission tomography
(PET) with [11C]harmine. Eight of the volunteers were given daily doses of 800 mg esuprone, four were given bi-daily doses of 300 mg moclobemide,
and four volunteers were given placebo tablets. PET was performed before initiation of a 7-day treatment period. On day 7,
one investigation was made immediately before administration of the drug, representing 23 h after the previous day's treatment
for esuprone and 11 h after the last tablets of moclobemide. Further investigations were made 4 h and 8 h after the morning
dose on day 7. Results: PET showed a high degree of binding of [11C]harmine, a high-affinity ligand for MAO-A, before the start of treatment, and a marked and similar reduction after treatment
with esuprone and moclobemide. A slight tendency for normalisation of enzyme binding was observed at the last time point.
In the placebo group no change was observed. Plasma kinetics of esuprone showed a rapid elimination with a half-life of about
4 h. Conclusion: The study demonstrates that esuprone was comparable to moclobemide in its effect on MAO-A inhibition in the brain at the
doses given. This is an illustration of the potential of PET to monitor drug effects directly on target biochemical systems
in the brain in human volunteers, and the possibility of using these data, rather than pharmacokinetic data, for the determination
of dosing intervals.
Received: 21 August 1996 / Accepted in revised form: 22 November 1996 相似文献
93.
Prospective study of antigenemia,plasma viremia and lymphocytic viremia in HIV-infected hemophiliacs
S. Melón Garcia M. de Oña Navarro C. Rodriguez Pinto M. Fernández Urgellés A. Martinez Gutierrez P. de la Iglesia F. J. Mendez García 《European journal of clinical microbiology & infectious diseases》1995,14(5):400-405
A total of 186 blood samples from 24 HIV-1 seropositive hemophiliac patients, monitored every four months for 29 months, were investigated for the presence of viral antigen in plasma. In addition, peripheral blood mononuclear cells (PBMC) were cultured for HIV-1, using normal PBMC as a target for replication. Antigenemia was detected in 51 % of the patients and from PBMC in 87.5 % of the patients. The incidence of HIV isolation in asymptomatic patients (42.8 %) was similar to that found in symptomatic patients (51.4 %). Patients with opportunistic infections had a higher incidence of lymphocytic viremia (p<0.05). Plasma viremia was closely associated (p<0.05) with low CD4+ counts and infection progression. The persistence of antigenemia was also a marker of a poor clinical course. In treated patients, plasma viremia was the marker that better correlated with the clinical course, and it did not appear during the first nine months of therapy. Zidovudine doses of >500 mg/day significantly lowered the appearance of antigenemia and lymphocytic viremia (p<0.05). 相似文献
94.
95.
96.
T. Scholz Ø. Mathisen A. Bergan S. Osnes R. Innes T. Pedersen A. O. Aasen O. Søreide 《Transplant international》1997,10(3):180-184
We have introduced and evaluated several modifications of the conventional venovenous bypass (VVBP) in 29 adult patients
undergoing liver transplantation (OLT). A percutaneous technique for insertion of a jugular venous return cannula and a femoral
vein cannula was applied. The inferior mesenteric vein (IMV) was used for splanchnic decompression, which facilitated dissection
of the recipient liver and allowed portal anastomosis to be performed without disconnecting the portal bypass. A heat exchanger
was introduced into the bypass circuit to prevent heat loss. The percutaneous technique prevented complications related to
dissection in the axilla and groin. Hemodynamic characteristics corresponded to those found using the traditional technique.
Complications related to the VVBP were seen in only one patient in whom the femoral catheter was accidentally introduced into
the femoral artery. We conclude that percutaneous cannulas, use of the IMV for splanchnic decompression and the introduction
of a heat exchanger offer significant benefits and that they are safe and reliable.
Received: 23 August 1996 Received after revision: 14 January 1997 Accepted: 27 January 1997 相似文献
97.
Drug related hospital admissions 总被引:13,自引:0,他引:13
J. Hallas B. Harvald J. Worm J. Beck-Nielsen L. F. Gram E. Grodum N. Damsbo J. Schou H. Kromann-Andersen F. Frølund 《European journal of clinical pharmacology》1993,45(3):199-203
Summary As part of a high-intensity monitoring study of drug events as the cause of admission to departments of internal medicine, the effect of an educational intervention programme was studied. Two departments were included, one specialising in geriatrics and one that received patients by non-selected referral. The series consisted of 607 consecutive admissions studied before and 703 after the intervention. The drug events considered were adverse drug reactions and dose-related therapeutic failures, mainly due to non-compliance.A modest, statistically non-significant decrease in drug related hospital admissions (DRH) was seen, from 14% before to 13% after the intervention period. However, DRHs classified as definitely avoidable showed the significant decrease of 83%.There was no apparent relationship between the topics selected for the intervention programme and changes in the pattern of DRHs. No relationship between alterations in sales data and hospital admissions caused by a given drug could be demonstrated. A blinded external evaluation of case abstracts did not disclose any significant shift in the investigators' assessments.The intervention may have had an non-specific effect on avoidable DRHs. 相似文献
98.
Nephrotic syndrome in a mother and her infant: relationship with cytomegalovirus infection 总被引:1,自引:0,他引:1
Marisa Giani Alberto Edefonti Beatrice Damiani Giuseppina Marra Daniela Colombo Giovanni Banfi Emilio Rivolta Erich H. Strøm Michael Mihatsch 《Pediatric nephrology (Berlin, Germany)》1996,10(1):73-75
This case report describes infantile nephrotic syndrome (NS) in a baby girl with a clinically severe cytomegalovirus (CMV) infection. Culture of the baby's urine was positive for CMV and IgM anti-CMV antibodies were detected. After an unsuccessful course of corticosteroids, gancyclovir treatment was started and a remission of cutaneous, pulmonary, and renal symptoms was achieved. As the mother also developed NS at the end of pregnancy, a common etiology could be postulated, although there were no signs of recent CMV infection in the mother, only anti-CMV IgG. The relationship between CMV infection and glomerular disease is still unclear: NS may represent another manifestation of CMV disease. 相似文献
99.
Benign intracranial hypertension and recombinant growth hormone therapy in Australia and New Zealand
PA Crock JD McKenzie AM Nicoll NJ Howard W Cutfield LK Shield G Byrne 《Acta paediatrica (Oslo, Norway : 1992)》1998,87(4):381-386
Benign intracranial hypertension (BIH) is reported in three children from Australia and one from New Zealand, who were being treated with recombinant human growth hormone (rhGH). Three males and one female, aged between 10.5 and 14.2 y, developed intracranial hypertension within 2 weeks to 3 months of starting treatment. A national database, OZGROW, has been prospectively collecting data on all 3332 children treated with rhGH in Australia and New Zealand from January 1986 to 1996. The incidence of BIH in children treated with growth hormone (GH) is small, 1.2 per 1000 cases overall, but appears to be greater with biochemical GHD (<10IUml -1 ), i.e. 6.5/1000 (3 in 465 cases), relative risk 18.4, 95% confidence interval 1.9-176.1, than in all other children on the database. The incidence in patients with Turner's syndrome was 2.3/1000 (1 in 428 cases). No cases in patients with partial GHD (10–20 IUml -1 ) or chronic renal failure were identified. Possible causative mechanisms are discussed. The authors'practice is now to start GH replacement at less than the usual recommended dose of 14IUm-2 week-1 in those children considered to be at high risk of developing BIH. Ophthalmological evaluation is recommended for children before and during the first few months following commencement of rhGH therapy and is mandatory in the event of peripheral or facial oedema, persistent headaches, vomiting or visual symptoms. The absence of papilledema does not exclude the diagnosis. 相似文献
100.